Vectura CEO to step down

10 June 2019

UK developer of inhaled therapeutics Vectura (LSE: VEC) today announces that James Ward-Lilley will be stepping down from the Board and his position as chief executive on June 30, 2019.

54-year-old Mr Ward-Lilley has been in the post since September 2015 and news of his planned departure saw Vectura’s shares rise 2.79% to 81.26 pence in early trading.

Paul Fry, currently chief financial officer, will assume the role of CEO in an interim capacity, in addition to his current responsibilities. A search for a CEO successor will begin immediately.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK